Business
Page 1 to 16 of 68 |     NEXT PAGE >
The Discoverome creative destruction of barriers for faster to patient medicines R&D By Chris Molloy
Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Read More

Filling the drug discovery abyss - novel business models to push through the valley of death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Winter 16/17
Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved around 200 novel drugs for human use (1,2). Not a large number considering the Pharmaceutical Research and Manufacturers of America (PhRMA) citation that for every 5,000 to 10,000 compounds that enter the pipeline, only one receives approval (3)

Read More

Digital pharma - responding to challenges and opportunities from outside - How digital is reshaping the pharma arena. By Ulrica Sehlstedt, Nils Bohlin, Fredrik de Mare and Richard Beetz Spring 2016
The pharmaceutical industry in the 20th and early 21st century has been in constant change, driven by both incremental and breakthrough innovations.

Read More

The benefits of not competing. By Richard Holland Fall 2015
Pre-competitive collaboration allows a group of competing companies to come together to develop a solution for a problem that they all share, and from which none of them would gain a competitive advantage.

Read More

Overcoming the Disruption Dip in the aftermath of M&A By Roger Humphrey Fall 2015
M&A deals are disrupting the life science industry – and that’s good, mostly. Yet, when a company reshapes its facilities footprint in the wake of a consolidation, cost efficiency can be undermined by the dreaded ‘disruption dip’ in productivity. Here’s how to keep your workplaces and laboratories on track.

Read More

Brothers in Arms: BioPharma and CROs collaborating in early drug discovery. By Dr John Montana and Cornelis E.C.A. Hop Summer 2015
BioPharma and CROs are riding the latest wave – discovery research – together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and how well they function, can vary widely, though.

Read More

A systemic malady: the pervasive problem of misconduct in the biomedical sciences part 2: detection and prevention. By Dr Gerald H. Lushington and Rathnam Chaguturu Summer 2015
Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge.

Read More

The Chinese Biologics Drug Market: demand and execution. By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu Spring 2015
In the past decade, China’s drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part II: business review. By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld Spring 2015
There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.

Read More

A systemic malady: the pervasive problem of misconduct in the biomedical sciences part I: issues and causes. By Dr Gerald H. Lushington and Rathnam Chaguturu Spring 2015
Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results – an affliction that has reached epidemic proportions and is now a global crisis spanning developed and developing countries alike, with much of the problem arising from scientific misconduct.

Read More

Data-mining open source databases for drug repositioning using graph-based techniques. By Dr Ken McGarry & Ukeme Daniel Winter 2014
The analysis of ‘Big Data’ has great potential in drug discovery; however complications arise in integrating this data in a principled and coherent way.

Read More

Principles for winning digital health strategies. By Dr Thilo Kaltenbach Fall 14
In a recent study on digital health in the pharmaceutical industry, management consultancy Arthur D. Little provided an industry snapshot of pharmaceutical companies’ goals for 2020 and their progress so far. The study indicated that by 2020, the business model of the pharmaceutical industry would be transformed by digital health.

Read More

Reconfiguring drug discovery through innovative partnerships. By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Fall 14
Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards of $4 billion, if one takes into account the cost of failed development candidates.

Read More

Collaboration for innovation is the new mantra for the pharmaceutical industry. By Professor Jackie Hunter Spring 2014
In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of appropriate knowledge and expertise outside of their own organisations is paramount. This article discusses some of the challenges in arranging collaborative arrangements with each other and academia.

Read More

How digital innovation and collaboration is driving a global demand for effective reporting in research funding. By Frances Buck Spring 2014
The UK, Europe and the United States are world leaders in research and innovation, with their researchers making vast contributions to global knowledge. They have world-leading universities, research institutes and scientific enterprises, supported by a public and private sector that has continued to invest in technology and innovation, despite the global economic downturn.

Read More

Building new models of drug discovery in Europe the Innovative Medicines Initiative. By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman Spring 2014
The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion for a compound to navigate its way along the drug discovery and development process – and only 8% of drug candidates entering clinical development make it to market and benefiting the patient2.

Read More

Business
Page 1 to 16 of 68 |     NEXT PAGE >